Overview

Temocillin Pharmacokinetic in Hemodialysis

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
0
Participant gender:
All
Summary
The current study aimed to explore the pharmacokinetics of temocillin in patients treated with haemodialysis and to demonstrated whether or not the pharmacodynamics target of a time above a MIC of 16 mg/L of more than 40 and 60 % of the dosing interval could be obtained with a dosing schedule of 1 gram/24 hours, 2 gram/48 hours and 3 gram/72 hours, all of these doses given after haemodialysis sessions only.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AZ Sint-Jan AV
Collaborators:
Ana Miranda Bastos, Louvain drug research institute, belgium
Francoise Van Bambeke, Louvain drug research institute, belgium
Paul Tulkens, Louvain drug research institute, belgium
Treatments:
Penicillins
Temocillin
Criteria
Inclusion Criteria:

- all patients under treatment with haemodialysis for ESRD for whom a treatment with
temocillin was indicated according to the attending physician were eligible for the
study.

Exclusion Criteria:

- an age of less than 18 years

- an estimated life-expectance of < 24 hours due to major co-morbid conditions

- pregnancy

- an IgE-mediated allergy to penicillins

- patients not giving informed consent.